BIO-Europe Digital comes at a time when global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward. Join the BIO-Europe Digital to schedule virtual partnering meetings, recorded content, some live sessions and virtual networking opportunities during the week of October 26–29.
Mogrify® has developed a proprietary direct cellular conversion technology, which makes it possible to convert any source human cell type into any target human cell type. The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways all together effecting a direct transdifferentiation between a mature cell type to another mature cell type.
Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, cell therapies, biomanufacturing and research tools to develop cell therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas.